Skip to main content
Download PDF

Volume 15 Supplement 2

Abstracts of the 2nd International Genomic Medical Conference (IGMC 2013)

Prognostic significance of fibroblast growth factor 19 (FGF19) expression in breast invasive ductal carcinoma

BMC Genomics volume 15, Article number: P35 (2014) Cite this article

Background

Several studies have shown that both FGF19 mRNA and protein are widely distributed in human tissues where they play an important role in cell proliferation, differentiation and motility (1-3). As part of our systematic search for prognostic markers in breast cancer (BC), the present study was conducted to assess the prognostic value of FGF19 in patients with BC.

Materials and methods

Archival FFPE tumor samples were analyzed using immunohistochemistry (IHC) for monoclonal anti-FGF19 (W12) antibody in 193 patients with BC. IHC analysis was done using the automatic system (Bench-Mark XT; Ventana Medical Systems, Inc. Tucson, AZ, USA). Patients were diagnosed and treated at the Departments of Pathology, Surgery and Oncology, King Abdulaziz University Hospital, Saudi Arabia and the National Oncology Institute, Sabratha, Libya during years 2000-2008.

Results

The expression pattern of FGF19 was predominantly cytoplasmic in the tumor area. Of the 193 tumors, 40% were considered low FGF19 expression, whereas 60% were considered high FGF19 expression. Interestingly, in lymph node positive patients, there was highly significant correlation between FGF19 expression and age of patients (p=0.008). Moreover, FGF19 expression showed significant correlation with tumor recurrence (p=0.02). Interestingly, in univariate (Kaplan-Meier) survival analysis, FGF19 expression was differentiating the DSS of lymph node positive tumors more significantly than the lymph node negative tumors (p<0.0001, log rank), in that tumors of lymph node positive patient with high FGF19 expression was more often, who eventually died of their disease (shorter disease specific survival (DSS)) as compared with those who were alive at the completion of the follow-up. On the other hand, PR status, tumor stage and grade had no significant relationship with FGF19 expression.

Conclusions

Quantification of FGF19 expression seems to provide valuable prognostic information in BC, particularly in selecting lymph node positive patients who are at high risk for shorter DSS who might benefit from targeted therapy.

This work was financially supported by King Abdulaziz City for Science and Technology (KACST) under research no (ASTP -10-Med-1107-03).

References

  1. Lin BC, Desnoyers LR: FGF19 and cancer. Adv Exp Med Biol. 2012, 728: 183-94.

    Article  CAS  PubMed  Google Scholar 

  2. Wu X, Yan Q, Huang Y, et al: Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J Cell Mol Med. 2010, 14: 351-6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Nakayama Y, Miyake A, Nakagawa Y, et al: Fgf19 is required for Zebrafish lens and retina development. Dev Biol. 2008, 313: 752-66.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia

    Sahar Hakamy, Basmat Abdallah, Abdelbaset Buhmeida, Ashraf Dallol, Muhammad Abu-Elmagd, Mamdooh Gari, Adeel Chaudhary, Adel Abuzenadah & Mohammed Al-Qahtani

  2. KACST Technology Innovation Center in Personalized Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia

    Ashraf Dallol & Adel Abuzenadah

  3. Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia

    Adnan Merdad & Fatima Thubaity

  4. Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia

    Jaudah Al-Maghrabi

  5. Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia

    Mamdooh Gari, Adeel Chaudhary, Adel Abuzenadah & Mohammed Al-Qahtani

  6. King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia

    Taoufik Nedjadi

  7. Department of Oncology, National Cancer Institute, Sabratha, Libya

    Eramah Ermiah

Authors
  1. Sahar Hakamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Basmat Abdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abdelbaset Buhmeida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ashraf Dallol
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Adnan Merdad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jaudah Al-Maghrabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Muhammad Abu-Elmagd
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mamdooh Gari
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Adeel Chaudhary
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Adel Abuzenadah
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Taoufik Nedjadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Eramah Ermiah
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Fatima Thubaity
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mohammed Al-Qahtani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdelbaset Buhmeida.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Hakamy, S., Abdallah, B., Buhmeida, A. et al. Prognostic significance of fibroblast growth factor 19 (FGF19) expression in breast invasive ductal carcinoma. BMC Genomics 15 (Suppl 2), P35 (2014). https://doi.org/10.1186/1471-2164-15-S2-P35

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1471-2164-15-S2-P35

Keywords

  • Breast Cancer
  • Invasive Ductal Carcinoma
  • Disease Specific Survival
  • FGF19 Expression
  • Breast Invasive Ductal Carcinoma

BMC Genomics

ISSN: 1471-2164

Contact us